✦ LIBER ✦
Hyperion Catalysis signs agreements with Showa Denko
- Publisher
- Elsevier Science
- Year
- 2009
- Weight
- 57 KB
- Volume
- 2009
- Category
- Article
- ISSN
- 1351-4180
No coin nor oath required. For personal study only.
✦ Synopsis
Non-GAAP earnings in 2009
are expected to increase to $4.7/diluted share. GAAP earnings, which include amortization and stock compensation expenses, are expected to reach $3.5/diluted share. Revenue is expected to reach $5.2-5.4 bn in 2009. Genzyme is one of the world's leading biotechnology companies.